FDA Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug Development

Caroline J Jjingo, Shukal Bala, Ursula Waack, Mark Needles, Timothy J Bensman, Owen McMaster, Thomas Smith, Brandon Blakely, Irene Z Chan, Khalid Puthawala, Cheryl Dixon, Yongman Kim, Robert Lim, Philip Colangelo, Christopher St Clair, Sumathi Nambiar, Richard B Moss, Radu Botgros, Rohit Bazaz, David W DenningKieren A Marr, Shahid Husain, Lance Berman, Dale J Christensen, Charlotte Keywood, Russell G Clayton, Thomas J Walsh, Hyo Sook E Song, Sunita J Shukla, John J Farley

Department of Chemistry
Division of Immunology, Immunity to Infection and Respiratory Medicine
Division of Evolution, Infection and Genomics

US Food and Drug Administration (FDA)
Stanford University Medical Center
European Medicines Agency (EMA)
Johns Hopkins University
University of Toronto
Pulmocide Limited
TFF Pharmaceuticals
Zambon SpA
Aeremedea LLC
Weill Cornell Medicine
DRT Strategies

Research output: Contribution to journal › Article › peer-review

Sort by
Weight
Alphabetically

FDA Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug Development

Fingerprint

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry